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Behavioral disturbances are observed in most patients suffering from diabetes. According to some evidence,
pro-inﬂammatory cytokines have a key role both in diabetes and behavioral disorders, such as anxiety and
depression. In this study, the effect of chronic administration of loganin, as a bioﬂavonoid, was investigated on
pro-inﬂammatory cytokines and depression- and anxiety-like behaviors in streptozotocin-induced diabetes in male
Wistar rats. Blood levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were assessed by enzyme-
linked immunosorbent assay method. Depression- and anxiety-like behaviors were evaluated by forced swimming
test (FST), elevated plus maze (EPM), and open ﬁeld test (OFT), respectively. Body weight was also measured before
the interventions and after the experiments in all groups. Our ﬁndings show that loganin-treated animals had
signiﬁcantly lower serum concentrations of IL-6 and TNF-α compared with the diabetic group. In the EPM test,
loganin treatment signiﬁcantly increased the percentage of the open arm time and open arm entries. Moreover,
loganin treatment signiﬁcantly decreased the grooming time and restored distance traveled and center crossing in the
OFT. However, it decreased immobility time in the FST. Loganin treatment also signiﬁcantly restored body weight
gain and attenuated blood glucose changes in the diabetic rats. These results indicate that loganin possibly alleviates
depression- and anxiety-like behaviors associated with diabetes through lowering the blood glucose and
pro-inﬂammatory cytokine levels. More research is required to show the exact mechanism of antidepressant and
anxiolytic effects of loganin in diabetes.
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Introduction
Most people suffering from diabetes have a dysfunction in their nervous system (23). Recent
researches focus on the relationship between diabetes and behavioral changes (8, 42).
Depression and anxiety are two common psychological disorders in people with diabetes
(5). Anxiety is one of the most common psychiatric disorders. It affects many aspects of life
and is highly comorbid with depression (47). Patients with anxiety exhibit signiﬁcant risk for
load inability, which can also be seen in chronic diseases, like diabetes mellitus (38, 41). In
recent years, some of the studies have shown that the prevalence of symptoms of anxiety and
generalized anxiety disorders has increased in patients with diabetes (9, 41). There is also
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evidence that patients with type 2 diabetes display depression occurrence twice as high as the
general population (40).
To describe the pathogenesis of depression, several mechanisms have been suggested
including abnormalities in the circadian rhythm, increased inﬂammatory cytokines, hyper-
cortisolemia, and deﬁciency of monoamines. It has also been suggested that oxidative stress
is increased in patients with depression (4, 28). Moreover, many studies have shown that
dysregulation of the immune system is associated with depression and anxiety disorders
(15, 20). Therefore, according to the evidence, there is a close relationship between diabetes
and depression and anxiety disorders. In addition, previous studies have suggested an
association between impaired glucose control and levels of pro-inﬂammatory mediators
(30, 46).
Dysregulation in both the acquired and the innate immune systems is coupled to the
onset of insulin resistance and type 2 diabetes (10, 43). Poorly controlled diabetes leads to
hyperglycemia that affects the immune system and increases pro-inﬂammatory mediators,
such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein
(6, 34, 44). Therefore, pro-inﬂammatory factors could be the common underlying risk factors
for both diabetes and behavioral disorders.
Loganin is one of the various components of Cornus ofﬁcinalis, which is highly
respected in Chinese medicine. Previous studies have shown that loganin has anti-
hyperglycemic (39), anti-inﬂammatory, anti-shock, and anti-arrhythmic effects (48, 50).
Our previous research also showed that loganin signiﬁcantly decreased oxidative stress
products in the central nervous system of diabetic rats (1). Given the fact that loganin
possesses neuroprotective properties and cognitive enhancing effects and is capable of
regulating immune system function, there are suggestions about the therapeutic use of
loganin in the treatment of neurodegenerative diseases (1, 25).
The aim of this study was to investigate the effect of chronic administration of loganin
on the immune system and depression- and anxiety-like behaviors in the diabetic rats.
Materials and Methods
Rats
Adult male Wistar rats (N= 40), weighing 200–250 g, were obtained from Animal House of
Tabriz, University of Medical Sciences. The rats were housed three per cage in a standard
condition with 12-h light/dark cycle, 20–22 °C, 45%–55% humidity, free access to food and
water, and lights were switched on at 6:00 a.m. (2). All procedures were carried out in
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory
Animals. All experimental procedures were also approved by Regional Ethics Committee of
Tabriz University of Medical Sciences.
Experimental design
Seven days after adaptation, rats were randomly divided into ﬁve groups (n= 8): control
(con), diabetic plus saline (dia+ saline), diabetic plus imipramine (dia+ imipr), diabetic plus
diazepam (dia + diaz), and diabetic plus loganin (dia+ log). Experimental diabetes was
induced by intraperitoneal (i.p.) injection of a single dose of 60 mg/kg streptozotocin (STZ)
(Tocris, UK) (35). Fasting blood glucose levels were determined 72 h after STZ injection,
using a glucometer (Roche, Germany). Blood samples were collected from the tail vein of
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overnight (10 h) fasted rats. Rats were considered diabetic, if blood glucose levels exceeded
300 mg/dl. Conﬁrming diabetes (on day 4 following STZ injection), rats received saline
(1 ml), imipramine (15 mg/kg i.p.) (ScienceLab, USA) (7), or diazepam (1 mg/kg i.p.)
(Sigma, USA), 30 min before behavioral tests (14). The rats in the dia + log group received
40 mg/kg of loganin per os (Extrasynthese, France), which was administered at 9:00 a.m. for
10 consecutive days. On day 10, the behavioral tests were performed an hour after the loganin
administration.
Behavioral tests
Forced swimming test (FST). Behavioral tests were performed in the morning (10 a.m.–12 p.m.)
under low illumination. Brieﬂy, rats were individually placed in a Plexiglas cylinder (46 cm
in height with a 21-cm internal diameter) ﬁlled with water (23 ± 1 °C) to a depth of 30 cm.
Water was changed between each swim session. In the pretest session, rats were placed in
the water for 15 min (ﬁrst exposure). Then, 24 h later, a test session was performed and
immobility behavior of rats was recorded for 5 min (24). Immobility was deﬁned as the
ceasing of struggling and remaining ﬂoating motionless in the water by making movements
only necessary to keep the rat’s head above the water. Decreased immobility time is an
indicator of an antidepressant-like effect. A blinded experimenter to the treatments
analyzed video recording.
Elevated plus maze (EPM). The EPM test, one of the well-known methods for testing of
anxiety in rodents, was performed as previously described by our laboratory. Brieﬂy, EPM
was a cross-shaped maze whose apparatus consisted of two open arms (50 cm × 10 cm) and
two enclosed arms (50 cm × 10 cm × 40 cm). The maze was elevated to a height of 50 cm.
The rats were individually placed in the center of the maze facing an open arm and allowed
5 min of free exploration. All sessions were videotaped and the number of entries and the
time spent in the open and enclosed arms were measured. Entry was deﬁned when all four
paws of rats are set in the arms. Percentage of entries into open arms and time spent in open
arms were calculated as the standard anxiety indices as follows: (i) percentage of the open
arm entries (% OAE) [(the ratio of entries into the open arms to total entries) × 100] and
(ii) percentage of the open arm (% OAT) [(the ratio of time spent in the open arms to total
time spent in any arms) × 100]. Total arm entries were also considered as the index of
locomotor activity (11, 24).
Open ﬁeld test (OFT). The OFT is often used to assess anxiety-like behaviors in rodents. The
open ﬁeld apparatus was an arena (50 × 50 × 40 cm) with black plywood walls and a brown
ﬂoor divided into nine squares by black lines. Each rat was gently placed in the center of the
arena and allowed to freely explore the novel environment for 5 min. All behaviors including
distance traveled (cm), time spent in the center (s), grooming time (s), and the number of fecal
boli were recorded during the test period by an observer blinded to the treatments. Between
each session, the arena was cleaned with 70% ethanol and dried (32).
Blood sampling.At the end of the experiments, all the rats were sacriﬁced between 10:00 a.m.
and 12:00 p.m. Blood samples were collected from the heart apex and centrifuged at 4 °C at
4,000 rpm. Serum levels of IL-6 and TNF-α were measured using enzyme-linked immuno-
sorbent assay kits (eBioscience, San Diego, CA) according to the manufacturer’s protocols.
Statistical analysis
Results are presented as mean± standard error of the mean. All data were statistically
analyzed by the SPSS16 software package. For body weight changes, paired sample t-test,
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and for serum levels of IL-6, Kruskal–Wallis followed by Mann–Whitney’s post-hoc test was
used. For all other variables, one-way analysis of variance followed by post-hoc Tukey’s test
was used for multiple comparisons. Statistical signiﬁcance was regarded as p< 0.05.
Results
Loganin improved weight gain and blood glucose levels in diabetic rats
Body weight was measured before the interventions and after the experiments in all rats.
There was no statistically signiﬁcant difference among groups in body weight before the
experiments (Fig. 1A). We found that the rate of body weight in the dia+ saline group was
signiﬁcantly (p< 0.01) lower than their body weight before the interventions. The adminis-
tration of loganin signiﬁcantly (p< 0.05) improved body weight gain in the dia+ log
group.
Our results also demonstrated that blood glucose increased in the diabetic group
(p< 0.01) (Fig. 1B). However, loganin treatment signiﬁcantly (p< .05) decreased fasting
blood glucose in the dia+ log group in comparison with the dia+ saline group.
Fig. 1. Effect of loganin on (A) body
weight; paired t-test: *p< 0.05,
***p< 0.001, and (B) blood glucose
levels in different groups. Data are
expressed as mean± SEM (n= 8).
con: control; dia+ saline: diabetic
plus saline; dia+ imipr: diabetic plus
imipramine; dia+ diaz: diabetic plus
diazepam 1 mg/kg; dia+ log:
diabetic plus loganin. ***p< 0.001
versus control group and #p< 0.05
versus dia+ saline group
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Loganin decreased depression-like behaviors in diabetic rats
According to the results, the immobility time in the dia+ saline group was signiﬁcantly
(p< 0.01) more than in the con group (Fig. 2). There was also a signiﬁcant (p< 0.05)
difference in immobility time between dia+ imipr and dia+ saline groups (Fig. 2). More-
over, immobility time in the dia+ log (p= 0.06) group was less than that in the dia+ saline
group, although it was not signiﬁcant.
Loganin decreased anxiety-like behaviors in EPM and OFT in diabetic rats
EPM. Statistically signiﬁcant differences were observed in the % OAT (p< 0.01, Fig. 3A)
and % OAE (p< 0.05, Fig. 3B) in the dia+ saline group compared with the con group.
However, loganin (40 mg/kg) administration signiﬁcantly (p< 0.05) increased % OAT and
% OAE in the dia+ loganin group when compared with the dia+ saline rats. Nevertheless,
there was no signiﬁcant change in % OAT and % OAE between the dia+ diaz and
dia + saline groups. Moreover, there were no signiﬁcant differences in locomotor activity
among four groups (Fig. 3C). These results showed that diabetic rats exhibited an increased
amount of anxiety-like behaviors, which was alleviated by loganin.
OFT. Our results showed that diabetic rats had signiﬁcantly (p< 0.01) less center-crossing
time (Fig. 4A), lower distance traveled (Fig. 4B), and more grooming time (Fig. 4C) and fecal
boli number (Fig. 4D) than the con animals. Importantly, loganin treatment signiﬁcantly
(p< 0.05) restored center crossing, distance traveled, and decreased the grooming time
compared with the diabetic group. Similarly, diazepam treatment signiﬁcantly (p< 0.05)
increased center-crossing time and distance traveled, and decreased fecal boli number in
comparison with the diabetic group.
Loganin decreased serum concentration of IL-6 and TNF-α in diabetic rats
This study showed that induction of diabetes signiﬁcantly (p< 0.01) increased the serum
concentrations of IL-6 (Fig. 5A) and TNF-α (Fig. 5B) when compared with the con
group. Nevertheless, loganin treatment signiﬁcantly (p< 0.05) reduced serum levels of
IL-6 (Fig. 5A) and TNF-α (Fig. 5B) in diabetic rats. Similarly, administration of imipramine
to diabetic rats signiﬁcantly reduced serum levels of IL-6 (p< 0.01, Fig. 5A) and TNF-α
(p< 0.05, Fig. 5B).
Fig. 2. Effect of loganin on immobility time between
different groups in FST. Data are expressed as
mean± SEM (n= 8). con: control;
dia+ saline: diabetic plus saline; dia+ imipr: diabetic
plus imipramine; dia+ diaz: diabetic plus diazepam
1 mg/kg; dia+ log: diabetic plus loganin. **p< 0.01
versus control, #p< 0.05 versus dia+ saline group
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Discussion
Anxiety and depression are common comorbid conditions in type 1 (18) and type 2 (5)
diabetes. Although the relationship between type 1 diabetes and anxiety disorders has been
demonstrated earlier (18), the nature of this relationship is yet to be elucidated (33). Previous
studies have suggested that fear of future hypoglycemic episodes results in high levels of
anxiety and stress in the patients suffering from diabetes (17, 21).
There is also an interrelationship between the severity of diabetes and depressive mood.
Poor glucose control and diabetes complications result in an increased prevalence of
depression in patients (45). Inﬂammation is a mechanistic link between depression and
diabetes (43). In this study, we investigated the effect of loganin on the serum levels of IL-6
Fig. 3. Effect of loganin on the percentage of open arm time (% OAT) (A), the percentage of open arm entries
(% OAE) (B), and locomotor activity (C) between different groups in EPM. Data are expressed as mean± SEM
(n= 8). con: control; dia+ saline: diabetic plus saline; dia+ imipr: diabetic plus imipramine; dia+ diaz: diabetic plus
diazepam 1 mg/kg; dia+ log: diabetic plus loganin. *p< 0.05 and **p< 0.01 versus control, #p< 0.05 versus
dia+ saline group
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and TNF-α, as pro-inﬂammatory cytokines, and depression- and anxiety-like behaviors in
STZ-induced type 1 diabetes.
This study showed that treatment with loganin (40 mg/kg) for 10 days increased the
body weight and reduced blood glucose levels in diabetic rats. Similarly, Liu et al. (27)
showed in their study that loganin treatment improved body weight gain and reduced blood
glucose levels in diabetic mice. In diabetes, chronic hyperglycemia leads to oxidative stress
by increasing reactive oxygen species (ROS) production and glucose autooxidation (13).
High levels of ROS trigger protein-kinase C production through diacylglycerol and elevate
production of cytokines involved in inﬂammation, speciﬁcally IL-6, which is known to be the
essential intermediary of acute inﬂammatory response (37). Our previous study demonstrated
that loganin decreased oxidative stress in diabetic rats (1).
The results of FST indicated that diabetes increased immobility time, as an index of
depression-like behaviors. These results are in line with a previous study reporting that
diabetic rats show depression-like behaviors in FSTs (16). Imipramine is one of the most
effective drugs for the treatment of depression and is used as a positive control in studies on
depression (7). In this study, imipramine and loganin (40 mg/kg/10 days) reduced immobility
Fig. 4. Effect of loganin on distance traveled (A), center crossing (B), grooming (C), and number of fecal boli (D)
among different groups in OFT. Data are expressed as mean± SEM (n= 8). con: control; dia+ saline: diabetic plus
saline; dia+ imipr: diabetic plus imipramine; dia+ diaz: diabetic plus diazepam 1 mg/kg; dia+ log: diabetic plus
loganin. *p< 0.05 and **p< 0.01 versus control, #p< 0.05 versus dia+ saline group
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time in FST, although there was no signiﬁcant difference between dia+ loganin and
dia + saline groups, possibly due to an inadequate dose of loganin for treatment.
Anxiety behaviors are one of the most common psychological disorders. Smith et al.
(41) indicated that diabetes is associated with anxiety behaviors. EPM and OFT are reliable
tests for investigation of anxiety-like behaviors in rodents (32). In this study, EPM results
showed that rats in the diabetic groups exhibited more entries into the closed arms and time
spent in the closed arms, which were reversed by loganin treatment. Frassetto et al. (14) used
diazepam (1mg/kg) as a positive control in their study for its anxiolytic effect and showed that
administration of diazepam increased the percentage of entries and time spent in the open
arms when compared with diabetic rats. This study has failed to demonstrate this result and
there was no apparent anxiolytic activity of diazepam in diabetic rats in EPM. Ramanathan
et al. (36) also demonstrated that diazepam (1 mg/kg) does not have an anxiolytic activity in
diabetic rats. Moreover, OFT results in the diabetic rats showed less center-crossing time,
lower distance traveled, and more grooming time and defecation. These results indicated that
diabetes increased anxiety-like behaviors. In contrast to the EPM results, the results of OFT
showed that diazepam signiﬁcantly increased center-crossing time, distance traveled, and
decreased defecation. On the other hand, administration of loganin markedly attenuated these
changes in the OFT.
Fig. 5. Effect of loganin on serum
concentrations of IL-6 (A) and
TNF-α (B) in different groups.
Data are expressed as mean± SEM
(n= 8). con: control; dia+ saline:
diabetic plus saline; dia+ imipr:
diabetic plus imipramine;
dia+ diaz: diabetic plus diazepam
1 mg/kg; dia+ log: diabetic plus
loganin. **p< 0.01 versus control,
#p< 0.05, ##p< 0.01 versus
dia+ saline group
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Increased anxiety-like behaviors in diabetic rats were associated with higher levels of
blood glucose, IL-6, and TNF-α. A previous study also speciﬁed that administration of
TNF-α to an animal-induced insulin resistance, whereas TNF-α neutralization improved
insulin sensitivity (31). It has been shown that activation of the inﬂammatory system is
related to the behavioral disorders. Inﬂammation and oxidative stress have major roles in the
pathogenesis of depression (12), anxiety (47), and diabetes (49). The results of meta-analysis
studies showed that pro-inﬂammatory cytokines, such as IL-6 and TNF-α, have an important
role in the molecular mechanism of depression- and anxiety-like behaviors (19, 29). In this
study, depression- and anxiety-like behaviors were accompanied by higher serum levels of
IL-6 and TNF-α in the diabetic rats. However, loganin treatment decreased serum IL-6 and
TNF-α concentrations and improved depression- and anxiety-like behaviors. In agree-
ment with the previous studies (3, 22, 26), our ﬁndings also showed that loganin has an
anti-inﬂammatory effect.
Based on the above documents, loganin treatment decreased depression- and anxiety-
like behaviors in the diabetic rats, possibly through attenuation of blood glucose and
pro-inﬂammatory cytokine levels. Further investigations are required to determine the exact
physiological mechanisms leading to antidepressant and anxiolytic effects of loganin. To our
knowledge, this was the ﬁrst study performed to clarify the effects of loganin in depression-
and anxiety-like behaviors in the diabetic rats.
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